Non-infectious Uveitis
Showing 1 - 25 of >10,000
Non-infectious Uveitis Trial (care strategy)
Not yet recruiting
- Non-infectious Uveitis
- care strategy
- (no location specified)
Jun 26, 2023
Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate Trial in Waltham (Ixekizumab Prefilled Syringe)
Recruiting
- Uveitis, Posterior
- +3 more
- Ixekizumab Prefilled Syringe
-
Waltham, MassachusettsMassachusetts Eye Research and Surgery Institution
Oct 11, 2023
Active Non-anterior Non-infectious Uveitis Trial (Baricitinib 4 MG)
Not yet recruiting
- Active Non-anterior Non-infectious Uveitis
- Baricitinib 4 MG
- (no location specified)
Dec 7, 2022
YUTIQ® 0.18 mg Intravitreal Implant for Management of Chronic
Recruiting
- Uveitis
- YUTIQ
-
Tianjin, Tianjin, ChinaTianjin Medical University Eye Hospital
Oct 23, 2022
Uveitis, Uveitis, Posterior, Uveitis, Intermediate Trial in Waltham (Sham Injector, FAI Insert)
Active, not recruiting
- Uveitis
- +2 more
- Sham Injector
- FAI Insert
-
Waltham, MassachusettsEyePoint Study Site
Dec 20, 2022
Non-infectious Uveitis Trial in Cleveland, Arlington, Houston (EYS606)
Completed
- Non-infectious Uveitis
- EYS606
-
Cleveland, Ohio
- +2 more
Mar 9, 2022
Uveitis, Adalimumab Trial in Guangzhou (reduction or discontinuation of Adalimumab)
Recruiting
- Uveitis
- Adalimumab
- reduction or discontinuation of Adalimumab
-
Guangzhou, Guangdong, ChinaZhongshan Ophthalmic Center, Sun Yat-sen University
Dec 9, 2021
Pathophysiology of Non-infectious Active Uveitis
Recruiting
- Non-Infectious Active Uveitis
- s-CD95-L
-
Bordeaux, FranceCHU Bordeaux
Apr 11, 2022
Non-infectious Uveitis Trial in France, United Kingdom (pEYS606)
Completed
- Non-infectious Uveitis
- pEYS606
-
Grenoble, France
- +3 more
Mar 9, 2022
Uveitis, Uveitis, Posterior, Uveitis, Anterior Trial in Plano (Yutiq 0.18 MG Drug Implant, Sham Injection)
Not yet recruiting
- Uveitis
- +3 more
- Yutiq 0.18 MG Drug Implant
- Sham Injection
-
Plano, TexasTexas Retina Associates
Aug 3, 2022
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis Trial (Ozurdex 0.7mg Ophthalmic Implant, Prednisone)
Recruiting
- Uveitis, Posterior
- +2 more
- Ozurdex 0.7mg Ophthalmic Implant
- Prednisone
-
Ottawa, Ontario, CanadaOttawa Hospital Research Institute - Vision Research Centre
Dec 14, 2022
Non-infectious Intermediate Posterior- or Pan-uveitis Trial in China (Adalimumab)
Recruiting
- Non-infectious Intermediate Posterior- or Pan-uveitis
-
Beijing, Beijing, China
- +7 more
Dec 6, 2022
Uveitis Trial in United States (Izokibep, Prednisone/Prednisolone)
Active, not recruiting
- Uveitis
-
Los Angeles, California
- +3 more
Jul 18, 2022
Uveitis Posterior Non-Infectious, Uveitis, Intermediate, Noninfectious Panuveitis Trial in Waltham, Erie (ESK-001)
Recruiting
- Uveitis Posterior Non-Infectious
- +2 more
-
Waltham, Massachusetts
- +1 more
Jul 18, 2023
Uveitis, Uveitis, Posterior, Uveitis, Anterior Trial in United States (4 mg CLS-TA Suprachoriodal Injection)
Completed
- Uveitis
- +4 more
- 4 mg CLS-TA Suprachoriodal Injection
-
Phoenix, Arizona
- +9 more
Jun 18, 2021
Uveitis, Posterior Trial in United States (Fluocinolone Acetonide Intravitreal Implant 0.18 mg)
Recruiting
- Uveitis, Posterior
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
-
Phoenix, Arizona
- +16 more
Aug 18, 2022
Uveitis, Cystoid Macular Edema Trial in Winston-Salem (Pegaptanib)
Completed
- Uveitis
- Cystoid Macular Edema
-
Winston-Salem, North CarolinaWake Forest University Eye Center
Mar 7, 2022
Uveitis Trial in Guangzhou (Adalimumab plus Methotrexate)
Recruiting
- Uveitis
- Adalimumab plus Methotrexate
-
Guangzhou, Guangdong, ChinaZhongshan Ophthalmic Center, Sun Yat-sen University
Dec 26, 2021
Non-infectious Anterior Uveitis Trial in Palisades Park, San Antonio (TRS01 eye drops)
Completed
- Non-infectious Anterior Uveitis
- TRS01 eye drops
-
Palisades Park, New Jersey
- +1 more
Aug 20, 2021
Non-infectious Uveitis Who Participated in CLS1001-301
Completed
- Uveitis
- +4 more
- 4 mg CLS-TA Suprachoriodal Injection
- Sham procedure
-
Phoenix, Arizona
- +15 more
May 13, 2021
Uveitis, Intermediate Uveitis, Posterior Uveitis Trial in Palo Alto (Intravitreal injection 440mcg, Intravitreal injection of
Recruiting
- Uveitis
- +3 more
- Intravitreal injection 440mcg
- Intravitreal injection of sirolimus 880mcg
-
Palo Alto, CaliforniaStanford University
May 5, 2021
Uveitis, Intermediate Uveitis, Posterior Uveitis Trial in Chicago, Omaha, Cleveland (triamcinolone acetonide (Triesence®))
Completed
- Uveitis
- +4 more
- triamcinolone acetonide (Triesence®)
-
Chicago, Illinois
- +2 more
Feb 17, 2021